Immunohistochemical staining for mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer

British Journal of Surgery

Volumn 94, Issue 8, 2007, Pages 1020-1027

  Ewald, J ^a,b   Rodrigue, C M ^b   Mourra, N ^a   Lefevre J H ^a,b   Flejou J F ^a   Tiret, E ^a   Gespach, C ^b   Parc, Y R ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN MLH1; PROTEIN MSH2;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; FEMALE; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MISMATCH REPAIR; PATIENT PARTICIPATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BASE PAIR MISMATCH; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; FEMALE; GENETIC TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION;

EID: 34547751430     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5704     Document Type: Article

References (31)

1. Thibodeau SN, Bren G, Schaid D. Micosatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
2. Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999; 45: 409-415.
3. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002; 15: 741-749.
4. Rigau V, Sebbagh N, Olschwang S, Paraf F, Mourra N, Parc Y et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 immunostaining. Arch Pathol Lab Med 2001; 127: 694-700.
5. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
6. Parc Y, Gueroult S, Mourra N, Serfaty L, Flejou JF, Tiret E et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53: 371-375.
7. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109: 468-471.
8. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-1762.
9. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860.
10. Cunningham JM, Kim C-Y, Christensen ER, Tester DJ, Parc Y, Burgart LJ et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69: 780-790.
11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
12. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-425.
13. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455-3460.
14. Mangold E, Pagenstecher C, Friedl W, Mathiak M, Buettner R, Engel C et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 2005; 116: 692-702.
15. Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003; 72: 1088-1100.
16. Hoogerbrugge N, Willems R, Van Krieken HJ, Kiemeney LA, Weijmans M, Nagengast FM et al. Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. Clin Genet 2003; 63: 64-70.
17. Kievit W, de Bruin JHFM, Adang EMM, Severens JL, Kleibeuker JH, Sijmons RH et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005; 54: 97-102.
18. Wijnen J, van der Klift H, Vasen H, Khan PM, Menko F, Tops C et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1998; 20: 326-328.
19. Wang Y, Friedl W, Lamberti C, Jungck M, Mathiak M, Pagenstecher C et al. Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 2003; 103: 636-641.
20. Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM et al. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 2000; 60: 2760-2763.
21. Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ et al. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 2002; 87: 892-897.
22. Baudhuin LM, Mai M, French AJ, Kruckeberg KE, Swanson RL, Winters JL et al. Analysis of hMLH1 and hMSH2 gene dosage alterations in hereditary nonpolyposis colorectal cancer patients by novel methods. J Mol Diagn 2005; 7: 226-235.
23. Baudhuin LM, Ferber MJ, Winters JL, Steenblock KJ, Swanson RI, French AJ et al. Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. Gastroenterology 2005; 129: 846-854.
24. Lamlum H, Al Tassan N, Jaeger E, Frayling I, Sieber O, Reza FB et al. Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet 2000; 9: 2215-2221.
25. Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA 1992; 89: 4452-4456.
26. Armstrong JG, Davies DR, Guy SP, Frayling IM, Evans DG. APC mutations in familial adenomatous polyposis families in the northwest of England. Hum Mutat 1997; 10: 376-380.
27. Heinimann K, Thompson A, Locher A, Furlanetto T, Bader E, Wolf A et al. Nontruncating APC germ-line mutations and mismatch repair deficiency play a minor role in APC mutation-negative polyposis. Cancer Res 2001; 61: 7616-7622.
28. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992; 340: 626-630.
29. Michils G, Tejpar S, Thoelen R, van Cutsem E, Vermeesch JR, Fryns JP et al. Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat 2005; 25: 125-134.
30. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GI, Halling KC et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004; 127: 9-16.
31. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456.